Demystifying the Compounding Conundrum: What We Should Know

On Demand available Webinar

Webinar

On Demand Available

Course Overview

Making the decision as to whether a compounded product can or should be used for your patient with cardiac disease can be confusing. While compounded drugs may be the best way to deliver a drug safely and effectively to your patient, using these animal products is fraught with risks. This webinar will wade through the hype and bring clarity to the regulations that impact the use of compounded animal drugs.

VETMEDIN® Solution (pimobendan oral solution) is the only oral solution product approved by the FDA for managing congestive heart failure (CHF) in dogs. Previous studies have shown that VETMEDIN® could help improve the survival time and quality of life for dogs with CHF due to myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM) when compared to dogs treated with an ACE inhibitor.

With VETMEDIN Solution you can confidently extend the benefits of VETMEDIN (pimobendan) Chewable Tablets to even more patients, strengthening their hearts and giving them more life to love.

Learning Objectives

1. Underscore situations in which the use of compounded animal drugs is appropriate.

2. Demonstrate the potential therapeutic risks associated with compounded animal drugs.

3. Demonstrate the different regulatory approach to animal drugs compounded from approved drugs versus bulk drug substances.

This course was made possible thanks to the generous support of Boehringer Ingelheim.

Back to the Course Catalog

Jump to:

Who Should Attend

ACVIM Diplomates and Candidates
European affiliate partners Diplomates and Candidates
Non-member DVMs
Specialty Technicians

Meet the Instructors

Dawn M. Boothe, DVM, MS, PhD, DACVIM (SAIM), DACVCP (Clinical Pharmacology)

Alumni Professor Emerita and Director of the Clinical Pharmacology Lab

Auburn University

Dr. Boothe graduated from Texas A&M University (TAMU) with a bachelor of science and DVM, later completing an MS in physiology, a residency in small animal internal medicine (becoming board certified in 1985), a PhrMA Fellowship, and a PhD in veterinary clinical pharmacology. She is among the first class of diplomates in the American College of Veterinary Clinical Pharmacology. In 1990, she joined TAMU, reaching professor in 2003. She then joined Auburn University’s College of Veterinary Medicine. After retiring from Auburn in 2022 as alumni professor emeritus, she joined the Veterinary Information Network, where she serves as an editor, consultant, and general provisioner of clinical pharmacology support.

Sonya Gordon, DVM, DVSc, DACVIM (Cardiology)

Professor of Cardiology

Texas A&M University

As an academic veterinary cardiologist, Dr. Gordon practices clinical medicine 30-40% of the time, which facilitates her research interests. She utilizes case material in clinical studies to answer practical relevant questions in veterinary cardiology with an emphasis on work that can be translated to primary care veterinary medicine. She has published manuscripts, book chapters and a textbook. Her interests and expertise in teaching have led to many invitations to organize and participate in continuing education events for veterinarians and veterinary cardiologists globally. These opportunities, coupled with her involvement in multicenter international studies, have provided her with a global perspective of veterinary cardiology. Dr. Gordon considers College Station, Texas home and shares her life with her husband, 2 dogs and 2 cats.

Sponsors

IMPORTANT SAFETY INFORMATION

VETMEDIN® Chewable Tablets is for use in dogs with clinical evidence of heart failure only. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. For full prescribing information, click here.

VETMEDIN® Solution (pimobendan oral solution) is for use in dogs with clinical evidence of heart failure only. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. For more information, call 888-637-4251 or see full prescribing information here.

VETMEDIN® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license.